The risk of graft-versus-host-disease (GVHD) bars a high proportion of leukemia patients from the benefits of a graft-versus-leukemia (GVL) effect. The goal of this project is to determine, in a murine model, whether GVHD can be controlled by using """"""""suicidal lymphocytes,"""""""" and if so, to optimize their use in the transplant setting. The immunologically mediated graft-versus-leukemia (GVL) effect noted after allogeneic bone marrow transplantation (allo BMT) is a powerful anti-leukemic, but its use as a therapeutic modality is limited by the development of GVHD. The risk of GVHD rises with patient age and donor-recipient mismatch. Current GVHD therapy is immunosuppressive: it treats the symptoms rather than eliminating the T cells that cause GVHD. Consequently many patients cannot benefit from a GVL effect. Controlling the fate of transplanted lymphocytes after infusion may permit limitation of severe GVHD while maintaining a GVL effect. Such therapy may improve the success rate of allogeneic transplantation; it may eliminate or reduce the barriers that prevent most leukemia patients from benefiting from the GVL effect. To create the ability to eliminate lymphocytes after infusion we propose to use a retrovirus to introduce a suicide gene, herpes simplex virus- thymidine kinase (HSV-TK), to sensitize the cells to ganciclovir (GCV). Normal human cells are insensitive to this drug. The suicide gene-bearing lymphocytes are then selected and expanded ex vivo and introduced into a patient to promote a GVL effect. If GVHD develops, it may be inhibited,a arrested, or terminated by administration of GCV. The proposed studies will determine the efficacy of these transduced lymphocytes in established murine models and investigate means of optimizing their use.
Specific Aim 1. Produce suicidal lymphocytes and test their function in vitro. Demonstrate infection, selection by FACS sorting, and expansion of murine lymphocytes transduced by a retrovirus containing the low-affinity nerve growth factor receptor and HSV-TK genes (LNGFR-TK). Demonstrate in vitro sensitivity to ganciclovir and in vitro alloimmune function of LNGFR-TK-infected lymphocytes.
Specific Aim 2. Demonstrate the ability of LNGFR-TK-infected lymphocytes to cause GVHD in mice and the ability to eradicate GVHD by in vivo administration of GCV. Determine the natural survival of infused lymphocytes. Optimize cell dose and timing of ganciclovir administration.
Specific Aim 3. Demonstrate that infusion of LNGFR-TK-infected lymphocytes into leukemia-bearing mice generates a GVL effect in a transplant setting.
Specific Aim 4. Optimize the anti-leukemic effect of the transplanted lymphocytes by combining strategies for separating GVL from GVHD with the use of the suicidal lymphocyte.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA049639-11
Application #
6332462
Study Section
Project Start
2000-07-12
Project End
2001-01-31
Budget Start
1997-10-01
Budget End
1998-09-30
Support Year
11
Fiscal Year
2000
Total Cost
$79,323
Indirect Cost
Name
University of Texas MD Anderson Cancer Center
Department
Type
DUNS #
001910777
City
Houston
State
TX
Country
United States
Zip Code
77030
Ruvolo, Peter P; Ruvolo, Vivian R; Burks, Jared K et al. (2018) Role of MSC-derived galectin 3 in the AML microenvironment. Biochim Biophys Acta Mol Cell Res 1865:959-969
Cortes, Jorge E; Gambacorti-Passerini, Carlo; Deininger, Michael W et al. (2018) Bosutinib Versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia: Results From the Randomized BFORE Trial. J Clin Oncol 36:231-237
Sasaki, Koji; Kantarjian, Hagop; O'Brien, Susan et al. (2018) Prediction for sustained deep molecular response of BCR-ABL1 levels in patients with chronic myeloid leukemia in chronic phase. Cancer 124:1160-1168
Gambacorti-Passerini, Carlo; Cortes, Jorge E; Lipton, Jeff H et al. (2018) Safety and efficacy of second-line bosutinib for chronic phase chronic myeloid leukemia over a five-year period: final results of a phase I/II study. Haematologica 103:1298-1307
Boddu, Prajwal; Shah, Abdul Rashid; Borthakur, Gautam et al. (2018) Life after ponatinib failure: outcomes of chronic and accelerated phase CML patients who discontinued ponatinib in the salvage setting. Leuk Lymphoma 59:1312-1322
Kornblau, Steven M; Ruvolo, Peter P; Wang, Rui-Yu et al. (2018) Distinct protein signatures of acute myeloid leukemia bone marrow-derived stromal cells are prognostic for patient survival. Haematologica 103:810-821
Zhang, Weiguo; Ly, Charlie; Ishizawa, Jo et al. (2018) Combinatorial targeting of XPO1 and FLT3 exerts synergistic anti-leukemia effects through induction of differentiation and apoptosis in FLT3-mutated acute myeloid leukemias: from concept to clinical trial. Haematologica 103:1642-1653
Alhuraiji, Ahmad; Kantarjian, Hagop; Boddu, Prajwal et al. (2018) Prognostic significance of additional chromosomal abnormalities at the time of diagnosis in patients with chronic myeloid leukemia treated with frontline tyrosine kinase inhibitors. Am J Hematol 93:84-90
Ishizawa, Jo; Nakamaru, Kenji; Seki, Takahiko et al. (2018) Predictive Gene Signatures Determine Tumor Sensitivity to MDM2 Inhibition. Cancer Res 78:2721-2731
Boddu, Prajwal; Benton, Christopher B; Wang, Wei et al. (2018) Erythroleukemia-historical perspectives and recent advances in diagnosis and management. Blood Rev 32:96-105

Showing the most recent 10 out of 375 publications